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Introduction
The concept of combination antiretroviral therapy (ART) for the 
treatment of HIV infection was established twenty years ago, 
when the results of the first studies evaluating protease inhibi-
tor-based regimens were published1. In recent years, several 
strategies of treatment optimization and simplification gained 
interest, with the objectives of improving quality of life, mini-
mizing ART-related toxicity and drug-drug interactions (DDI), 
as well as reducing health-related costs. So far, ART de-escala-
tion from three to one (mono-) or two drugs (dual-) therapies 
has mainly been evaluated in virologically suppressed patients. 
The first simplified maintenance strategy studied included a 
boosted protease inhibitor (bPI), with the hope that the high 
genetic barrier to resistance would help achieve durable viro-
logical suppression. In a meta-analysis including ten studies, bPI 
monotherapy was found to be inferior to triple ART for the 
maintenance of viral suppression2, but non-inferior with regards 
to loss of future treatment options3. In contrast, dual therapy 
with bPI and lamivudine (3TC) was found to be non-inferior to 
triple ART4–6 and is now recognized as a valid switch strategy by 
current HIV treatment guidelines in selected situations7. How-
ever, bPI-based maintenance strategies are not widely applicable 
because of cost, toxicity and DDI.
Due to its interesting pharmacokinetic profile, good tolerability 
and high barrier to resistance, dolutegravir (DTG), a new inte-
grase strand transfer inhibitor (InSTI), has attracted much 
interest for its use in simplified treatment regimens. While 
preliminary analyses of a Dutch DTG monotherapy simplification 
trial seemed encouraging at 24 weeks, rates of virological 
failures increased significantly by week 48, suggesting a sub- 
optimal potency of this regimen8. On the other hand, several 
studies evaluating DTG-based dual therapy with either 3TC 
or rilpivirine (RPV), showed a high virological efficacy9–12. 
However, most reports were from small, observational cohort 
studies, with the exception of one DTG-RPV industry-sponsored 
randomized controlled trial (RCT)11.
We performed a systematic review of the literature and a meta-
analysis to provide precise estimates of the rate of virological 
failure (VF) and drug resistance in patients switched to a DTG-
based maintenance mono- or dual therapy, and to clarify which 
drugs or combinations should be evaluated in further studies 
and implemented in clinical practice.
Methods
The protocol for this systematic review was written and regis-
tered with the International Prospective Register of Systematic 
Reviews (PROSPERO registration number CRD42017070045)13. 
The reporting of the review followed the PRISMA guidelines14 
(Supplementary File 1).
Search strategy and selection criteria
We searched Medline, EMBASE, Cochrane Central and Web of 
Science, as well as abstracts of major HIV conferences (CROI, 
AIDS, HIV Glasgow, AFRAVIH, IAS and EACS between 
2013 and 2017) on 4. January 2018 for studies assessing the 
proportion of individuals developing VF on DTG-based 
maintenance therapy. In Medline we combined free text words 
and medical subject headings (MESH) describing the study 
population and the outcome (Supplementary File 2). This search 
strategy was adapted for the other databases. We considered 
RCTs, single-arm clinical trials, cohort studies, and case-series 
that included at least five HIV-infected adults (≥18 years) on 
DTG-based simplified therapy. No language restrictions were 
applied. Studies had to report on virological outcomes of 
patients who switched to a DTG monotherapy or dual therapy 
after having an undetectable VL on triple ART. We excluded 
studies that only reported in vitro data and those selecting 
participants based on the outcome during DTG-based mainte-
nance therapy. Two investigators (MB and GW) independently 
selected studies based on titles and abstracts, and, in a 
second step, based on the full text of potentially eligible 
articles. Discrepancies in study selection were resolved through 
discussions with a third investigator (AC).
Data extraction
The following data were extracted independently for each 
study by two reviewers (GW and MB), using a standardized 
spreadsheet: bibliographic details, study design, inclusion and 
exclusion criteria, definitions of outcomes, country, number of 
participants and their main demographic and clinical charac-
teristics, including duration since HIV diagnosis, ART history, 
immunological status (CD4 cell count at switch and nadir) and 
virological parameters (HIV RNA peak and at baseline, HIV-
DNA at baseline and changes during the study, VF as defined 
by the study, and the presence at drug resistance at switch). 
Again, discrepancies in data extracted were resolved through 
discussions with a third investigator (AC).
Assessment of risk of bias
A checklist for the assessment of risk of bias was designed to 
ensure data quality assessment for each study was included. 
The form for RCTs included information on the sequence 
generation, allocation concealment, blinding (participants, person-
nel and outcome assessor), incomplete outcome data, selective 
outcome reporting and other sources of bias. The methodo-
logical components of the randomized trials were assessed by 
two independent authors and classified as high, low or unclear 
risk of bias, as recommended by the Cochrane collaboration15. 
For observational studies it was not appropriate to use the 
ROBINS-I tool16, as we only considered data from the group of 
patients on simplified, maintenance therapy. Thus, we assessed 
the population characteristics and missing outcome data for 
each study.
Data analysis
We described the study design as well as the demographic 
and clinical characteristics of the population from each study 
by type of maintenance therapy (DTG-based monotherapy or 
dual therapy). Pooled proportions of VF and treatment failure 
(VF or departure from simplified strategy due to toxicity, 
loss to follow-up, patient’s or physician’s decision), and 95% 
confidence intervals (CI) were estimated using random inter-
cept logistic meta-regression. These analyses were performed 
separately at 24 weeks and 48 weeks after the switch from 
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triple ART to maintenance therapy. For all models, statistical 
evidence for heterogeneity between studies was assessed using 
the tau-squared statistics17. We evaluated the association between 
type of maintenance strategy and VF using random intercept 
logistic meta-regression (binomial-normal) models. All models 
were adjusted for potential confounders, including age (median 
or mean), sex (proportion of female participants) and study type 
(interventional or observational). Furthermore, the proportion 
of participants acquiring new drug resistance mutations was 
assessed for each treatment strategy and the mutations described 
in detail. Statistical analyses were conducted in STATA version 
14.1 (StataCorp, Texas, USA) and R version 3.2.3 (R Core 
Team, Vienna, Austria).
Role of the funding source
The funder of the study had no role in the design, data 
collection, data analysis, data interpretation of the results or 
writing of the report. The corresponding author had full access 
to all the data in the study and had final responsibility for 
the decision to submit for publication.
Results
Study and participant characteristics
Of 1719 single studies identified, 63 remained potentially 
eligible after the screening of titles and abstracts. Of these, 21 
studies, including four RCTs, three single-arm clinical trials 
and 14 observational studies met our inclusion criteria8,11,12,18–35 
(Figure 1). A description of the main study characteristics by 
type of maintenance strategy is given in Table 1. Eight studies 
(two from France, two from The Netherlands, one from 
Germany, one from Switzerland and two from Spain) including 
251 patients assessed the switch to DTG monotherapy and 14 
(five from Italy, four from France, three for Spain, one from US, 
and one multi-country study), including 1670 participants, the 
switch to DTG-based dual therapy. Dual therapy consisted of 
DTG + 3TC (seven studies) or RPV (four studies) or atazanavir 
(ATV, two studies) or darunavir (DRV, one study). Overall, 
14 studies allowed the inclusion of patients with previous 
virological failure, including five monotherapy studies18–20,22–24. 
In one study, patients with previous InSTI failure were also 
included12. Nineteen studies assessed virological outcomes 
at six months of maintenance therapy, whereas ten of them 
additionally showed outcomes at one year8,11,12,24,27,29–33,35. Two 
studies assessed virological outcomes only at 48 weeks25,27. 
Median (or mean) age of participants included in the studies 
varied from 43 years11 to 63 years24 and 27.6% of them were 
female. 16 studies reported on the median nadir CD4 cell 
count, which ranged from 90 cells/µl12 to 399 cells/µl29.
Risk of bias
All RCTs were open-label non-inferiority trials8,18,35, of which one 
was a single center trial18 and three were multicenter trials8,11,35. 
Figure 1. Flow chart of study selection process.
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They reported adequate generation of random allocation 
sequences and allocation concealment. Three single-arm trials 
were included, of which two included less than 10 patients21,24,29. 
All interventional studies adequately addressed incomplete 
outcome data: proportions of drop-outs were low and outcome 
data were missing for less than 20% of participants in all studies. 
Five of seven trials reported on virological outcomes at both 
time-points of interest for this study (24 and 48 weeks)8,11,24,29,35. 
There was no evidence of selective reporting in any of the 
studies. In each of the 14 observational studies included in this 
review, the main demographic and clinical characteristics of the 
study populations were similar and patients were followed for 
24 weeks in most studies. Among the observational studies, 
the majority did not report detailed inclusion and exclusion 
criteria. Five observational studies reported virological outcomes 
at both time-points12,30–33. Amplification for drug resistance 
testing was successful for 19 of the 27 (70%) patients with VF. 
Finally, patient retention was over 90% in all 14 cohort studies.
Virological and treatment failure
The pooled estimate of the proportion of participants who expe-
rienced a VF on DTG-based monotherapy was 3.6% (95% 
CI 1.9-6.7) at 24 weeks and 8.9% (95% CI 4.7-16.2) at 48 weeks 
(Figure 2). The high proportion of treatment failures among 
Figure 2. Meta-analysis of virological failure among patients on single or dual DTG-based simplification therapy.
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patients on monotherapy at 48 weeks was driven by the two 
studies from the Netherlands, which observed between 8 and 
20% of VF8,24. Among patients on dual therapy, an estimated 
0.4% (95% CI 0.2-0.9) experienced a VF at 24 weeks and 0.7% 
(95% CI 0.4-1.3) at 48 weeks. Independently of the combina-
tion used (DTG/3TC, DTG/RPV, DTG/ATV or DTG/DRV), 11 
of 14 studies evaluating the effectiveness of dual therapy had 
less than 1% of patients developing VF. Compared to patients on 
monotherapy, those on dual therapy were less likely to experi-
ence VF by 24 weeks (odds ratio [OR] 0.10, 95% CI 0.03-0.32, 
p<0.001) and 48 weeks (OR 0.07, 95% CI 0.03-0.18, 
p<0.001). In analyses adjusted for study type (interventional 
or observational), age (median or mean) and sex (proportion of 
female participants), the OR for VF at 24 weeks and 48 weeks 
were very similar to the unadjusted estimates (aOR 0.10, 95% 
CI 0.03-0.30 for 24 weeks and aOR 0.06, 95% CI 0.01-0.30 for 
48 weeks, respectively). The only variable that contributed to 
explaining the between-study heterogeneity in both the 24 and 
48-week analyses was treatment strategy. When including 
this variable, the tau-squared were reduced from 1.17 (95% 
CI 0.33-2.19) to 0.00 (95% CI 0.00-1.11) in the 24 week analy-
sis and from 1.37 (95% CI 0.54-2.15) to 0.00 (95% CI 0.00-1.00) 
in the 48 week analysis. The inclusion of other variables did not 
impact the estimates of tau-squared.
Treatment failure occurred in 5.2% (2.0–12.9) of patients at 
24 weeks and 12.3% (4.5–29.4) at 48 weeks on DTG-mono-
therapy, whereas this outcome was observed in 2.8% (1.4–5.7) 
of patients at 24 weeks and 6.5% (4.3–9.6) at 48 weeks on 
DTG-based dual therapy. At 24 weeks, patients on dual therapy 
tended to be less likely to experience treatment failure com-
pared to those on monotherapy (aOR 0.52, 95% CI 0.15-1.85). 
Due to multi-collinearity in the model, we were not able to report 
on multivariable analyses comparing treatment failure between 
mono and dual therapy at 48 weeks.
Drug resistance
Acquired resistance mutations to InSTI developed in 9/251 
(3.6%) participants on DTG-based monotherapy, which corre-
sponded to 56% of the cases of VF (Table 2). Three individuals 

























Katlama et al. 24 28 4 (14.3) - 3 (10.7) - 3 3 E138K,G140A, Q148R 
E92Q 
N155H
Wijting et al. 48 96 - 11 (11.5) 2 (2.1) 8 (8.3) 6 3 S230R 
R263K 
N155H
Gubavu et al. 24 21 0 - 0 - - -
Oldenbüttel 
et al. 
24 31 2 (6.5) - 1 (3.2) - 1 1 Q148H, G140S
Rokx et al. 48 5 0 1 (20) 0 1 (20.0) 1 0
Rojas et al. 24 31 1 (3.2) - 1 (3.2) - 1 0 118R**
Lecompte et al. 24 8 1 (12.5) - 0 - - -




Borghetti et al. 24 36 3 (8.3) - 0 - - -
Maggiolo et al. 48 94 0 3 (3.2) 0 0 - -
Joly et al. 48 104 1 (1.0) 3 (2.9) 1 (1.0) 1 (1.0) 0 -
Reynes et al. 48 27 3 (11.1) 3 (11.1) 0 0 - -
Blanco et al. 24 29 1 (3.5) - 1 (3.4) - 1 0 K70E***, K219E***, 
G190R$, M230I$
Maggiolo et al. 48 203 0 12 (6.0) 0 0 - -
Taiwo et al. 48 44 1 (2.3) 3 (6.9) 1 1 1 0
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developed the Q148R or Q148H mutation in combination with 
other resistance mutations, conferring high-level resistance to 
DTG20,22. These three patients did not have a history of previous 
VF and had a suppressed HIV viral load for several years before 
switching to DTG-monotherapy. No InSTI resistance muta-
tions developed in patients on dual therapy. Of 962 patients on 
RPV/DTG, only one developed a major drug resistance mutation 
to non-nucleoside reverse transcriptase inhibitors (K101E). No 
resistance was observed in plasma among 237 individuals on 
DTG/3TC.
Dataset 1. Dolutegravir meta-analysis summary data
https://dx.doi.org/10.5256/f1000research.15995.d215724
This table shows summary measures, including the number of 
virological and treatment failures in each study.
Discussion
We performed a comprehensive systematic review of studies 
that reported on VF among patients switched to DTG-based 
maintenance therapy. Our meta-analysis shows that DTG-based 
dual therapy is successful in sustaining virological control 
in ART-experienced HIV-infected patients: only 12 of 1670 
(0.7%) experienced a VF and none of them developed resistance 
mutations to DTG. On the contrary, 16 of 251 (6.4%) indi-
viduals switched to DTG monotherapy had a VF, of which 
more than one-half developed resistance to DTG. Although 
the proportion of patients experiencing a confirmed viral 
rebound on DTG-monotherapy does not seem to be higher 
than in patients on PI-monotherapy, the risk of losing future 
treatment options is higher with DTG-monotherapy3. Over-
all, our findings suggest that DTG-based monotherapy is not 
an appropriate simplification strategy and that further studies 
are urgently needed to confirm the long-term efficacy of 
DTG-based dual therapy.
DTG-based dual therapy is a promising simplification strategy, 
especially when combined with 3TC or emtricitabine (FTC, both 
compounds referred to as XTC), as the likelihood of developing 
toxicity events and DDI on such regimens is very low. No drug 
resistance mutations to DTG developed among more than 1600 
patients on dual therapy followed for 24 to 48 weeks and only 
one had a resistance mutation to another drug class. Although 
based on very few patients, the results seemed to be independ-
ent of previous virological failures. For instance, no virological 
failures were noted among patients on DTG/3TC despite the 
presence of a 184V mutation at the time of simplification in 
several studies. The impact of the latter mutation on viral fitness 
has been extensively described and could also potentially explain 
the improved treatment outcomes in these patients compared 
to those switched to DTG-monotherapy without any previ-
ous failures. Interestingly, similar observations were made for 
bPI-based regimens, for which efficacy was improved when 
3TC was added, despite the presence of the 184V mutation36. 
Although the proportion of patients experiencing a confirmed 
viral rebound on DTG-monotherapy does not seem to be higher 
than in patients on PI-monotherapy, their chances of los-
ing future treatment options is higher than reported in most 
PI-monotherapy trials
We also report on estimates of treatment failure, which includes 
other reasons for treatment interruptions, such as toxicity or loss 
to follow-up. In our meta-analysis, the proportion of patients 
experiencing this combined outcome was more than twice as 
high among patients on monotherapy compared to those on 
DTG-based dual therapy. Although this outcome is important 

























Llibre et al. 48 513 - 27 (5.3) 1 (0.2) 2 (0.4) 2 1 K101K/E
Gantner et al. 24 116 11 (9.5) - 1 (0.9) - 0 -
Bonijoly et al. 24 268 - 51 (19.0) - 4 (1.5) - -
Revuelta et al. 48 32 - 2 (6.5) 0 0 - -
DTG-ATV
Riva et al. 24 61 3 (4.9) - 0 - - -
Castagna et al. 48 116 5 (4.3) 6 (5.2) - 1 (0.9) - -
DTG-DRV
Navarro et al. 48 27 - 2 (7.4) 0 1 (3.7) 1 0
*bold: InSTI resistance
**in 7% of integrated DNA in PBMC
*** in ≤1.5% of integrated DNA in PBMC
£ in integrated DNA in PBMC
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our capacity to analyze this outcome in detail was limited by 
the missing information on the specific reasons for treatment 
interruptions in many studies and by the small number of 
events, especially at 48 weeks of therapy.
Of all simplification strategies evaluated to date, the DTG/
XTC combination could be the one most readily accessible 
for patients in low- and middle-income countries: both DTG 
and XTC are available and prequalified by stringent regulatory 
authorities in generic formulations. In order to be widely imple-
mented, the efficacy of this dual combination should first be 
evaluated in large studies among different patient populations. 
The results from the studies included in our meta-analysis are 
mainly based on selected populations of HIV-infected individuals 
from European cohorts, and are not generalizable. Furthermore, 
long-term data are needed, as most treatment failures occurred 
after the first 24 weeks in several monotherapy studies. Recently, 
results from the only study which assessed 96-week outcomes 
with this regimen to date were reported: among 27 ART- 
experienced individuals with previous VF, DTG/3TC was 100% 
efficacious virologically12. However, despite these encouraging 
results, data from larger studies are needed. In addition, more 
data on the activity of DTG-based simplified regimens in com-
partments other than blood are needed. Letendre et al. showed 
that DTG achieved therapeutic concentrations in the central 
nervous system (CNS), with a CNS penetration effectiveness 
score of four37. However, these results were based on a very 
small sample of patients and data from individuals on simplified, 
DTG-based therapies are lacking.
As a wealth of data on the efficacy of DTG-maintenance strate-
gies from small studies are being disseminated at a fast pace, 
this systematic review is the first analysis to provide com-
parative estimates of virological failure between DTG-based 
monotherapy and dual therapy. More than 1700 studies were 
screened, including abstracts from all important HIV confer-
ences in the past years. As our meta-analysis included studies 
with diverse study designs and populations, it could be argued 
that the comparison of studies with such differences might be 
problematic. However, the estimates of VF were very simi-
lar across studies, especially in the DTG-based dual therapy 
arm. This finding highlights the potency of this combination, 
even in the presence of previous drug resistance muta-
tions or multiple co-morbidities. Unfortunately, only studies 
including low numbers of patients reported outcomes from 
individuals on DTG-monotherapy, and data on dual therapy was 
dominated by one large study that assessed the efficacy of the 
DTG/RPV combination. As a consequence, the comparison 
of DTG-monotherapy vs. DTG/XTC, which would have been 
the most interesting one, was not possible. Furthermore, the 
lack of availability of individual data from the different stud-
ies precluded the analysis of risk factors of VF in the different 
simplification regimens. As most studies were observational, 
it is possible that the investigators mainly included patients 
with good adherence, which may have limited the generaliz-
ability of their findings. Finally, our results might have slightly 
under-estimated the proportion of patients with VF as indi-
viduals who were lost to follow-up might have experienced 
this outcome without them being accounted for. However, our 
treatment failure estimates showed that even when other reasons 
of treatment failure were considered, DTG-based dual therapy 
was superior to monotherapy.
In summary, DTG-based dual maintenance therapy seems to be 
a promising simplification strategy with high virological efficacy 
and low potential for DDI and toxicity. Such a treatment regi-
men could be an interesting alternative to classical triple-ART 
in selected patients. Furthermore, dual therapy might be a 
cost-effective global ART strategy38. A number of large prospec-
tive studies evaluating the efficacy of DTG-based dual therapy 
are under way and will inform its potential implementa-
tion at a large scale. In addition to the studies on maintenance 
therapy39,40, clinical trials are also assessing the efficacy of 
DTG/XTC in treatment-naïve patients41. Furthermore, it will be 
critical to evaluate the efficacy of DTG-XTC dual therapy in 
specific sub-groups such as pregnant and breast-feeding women, 
adolescents, patients with previous failure to standard triple 
regimens and harboring the M184V resistance mutation, as 
well as in patients with HIV associated neurocognitive disorder 
and tuberculosis coinfection. 
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